semaglutide cardiovascular trial outcomes align more closely with attained dose than achieved weight loss π¨ Breaking News: Real-World Data
Description
This corresponded to a risk ratio of 0.90 for emergency department visits and 0.86 for hospitalizations
For a patient population that is often heading toward total joint replacement, that outcome is genuinely practice-changing
Even in legitimate Phase 3 trials, adverse events at the highest dose were significant
By stabilizing blood sugar levels and improving insulin sensitivity, it aids your body in burning fat more effectively and preventing the accumulation of excess weight
